The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 22, 2019

Filed:

Mar. 27, 2015
Applicant:

Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v., Munich, DE;

Inventors:

Alexander Boes, Cologne, DE;

Holger Spiegel, Aachen, DE;

Gueven Edgue, Aachen, DE;

Veronique Beiss, Aachen, DE;

Markus Sack, Alsdorf, DE;

Andreas Reimann, Krefeld, DE;

Rainer Fischer, Aachen, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/015 (2006.01); C07K 14/445 (2006.01); C07K 16/20 (2006.01); G01N 33/569 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/015 (2013.01); C07K 14/445 (2013.01); C07K 16/205 (2013.01); G01N 33/56905 (2013.01); A61K 2039/575 (2013.01); A61K 2039/70 (2013.01); C07K 2319/00 (2013.01); C07K 2319/21 (2013.01); G01N 2333/445 (2013.01); Y02A 50/412 (2018.01);
Abstract

The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several differentantigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins; Antibodies induced or generated by the use of said malaria vaccines or said nucleic acid molecules encoding said proteins and/or fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.


Find Patent Forward Citations

Loading…